Shahrnaz Khalaghi

Shahrnaz Khalaghi

Auto-generated profile, based on publicly available information

Shahrnaz Khalaghi

Department of Cardiology, Faculty of Medicine, Cardiovascular Research Center, Mazandaran University of Medical Sciences, Sari, Iran

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2023 in The Egyptian Heart Journal
Verified
Journal Article
Open access
PDF file
RJRozita Jalalian
Rozita Jalalian
BBBabak Bagheri
Babak Bagheri
JCJamshid Yazdani- Charati
Jamshid Yazdani- Charati
SKShahrnaz Khalaghi
Shahrnaz Khalaghi
MIMohammadreza Iranian
Mohammadreza Iranian
MMMahsa Mohammadi
Mahsa Mohammadi
Background: ST-segment elevation myocardial infarction (STEMI) is usually caused by a rupture in the atherosclerotic plaque, followed by platelet aggregation which ultimately leads to acute coronary artery occlusion. So far, few studies have investigated the effect of maintenance dose of Eptifibatide (glycoprotein IIb/IIIa inhibitor) in STEMI patients who underwent primary percutaneous coronary intervention (PPCI). Therefore, in this study, we investigated the effect of maintenance dose of Eptifibatide in patients with STEMI who underwent PPCI. 264 patients who had acute chest pain suggestive of STEMI were entered in the study. All patients received the same dose of bolus dose of Eptifibatide in the cardiac catheterization laboratory. Then the patients were randomly divided into two groups, one group (n = 147) received a maintenance dose of intravenous Eptifibatide (infusion of 2 μg/kg/min) and the other group (n = 117) did not receive this treatment. Standard medical treatment of STEMI after PPCI was performed based on guidelines and the same in both groups. All patients were evaluated 1, 2, and 3 months after the start of treatment in terms of predicted outcomes.Results: The occurrence of 3-month major adverse cardiovascular events (MACE) between the case and control groups did not have a statistically significant difference (28.6% versus 35.0%;Pvalue: 0.286). Also, investigations showed that the rate of re-infarction (Pvalue: 0.024) and target lesion revascularization (Pvalue: 0.003) was significantly lower in the group that received Eptifibatide infusion.Conclusions: Eptifibatide maintenance dose infusion in patients who undergo PPCI in the context of STEMI, does not significantly reduce MACE, although it does significantly reduce re-infarction and target lesion revascularization. It also does not increase the risk of bleeding and cerebrovascular events.